AKWEL: TURNOVER OF €528.8M IN THE FIRST HALF OF 2024 25-07-2024, 22:45

ResMed Announces Participation in the 2023 KeyBanc Life 16-03-2023, 03:22

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00